Rite Aid Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Standards

$RAD
Retail-Drug Stores and Proprietary Stores
Consumer Staples
Get the next $RAD alert in real time by email

Rite Aid Corporation (NYSE:RAD) (the "Company") announced today that the New York Stock Exchange (the "NYSE") informed the Company that it is no longer in compliance with NYSE continued listing standards set forth in Section 802.01B (the Minimum Market Capitalization Standard), and Section 802.01C (the Minimum Stock Price Standard) of the NYSE's Listed Company Manual.

Under the NYSE rules, the Company is provided with certain cure periods and the Company's common stock will continue to be listed and traded on the NYSE during the cure periods, subject to the Company's compliance with other continued listing requirements. The current noncompliance with the NYSE listing standards does not affect the Company's ongoing business operations or its U.S. Securities and Exchange Commission reporting requirements, nor does it trigger any violation of its material debt or other obligations. As previously disclosed, the Company has been engaged in reviewing and continues to review strategic alternatives to recapitalize, refinance or otherwise optimize its capital structure (the "Ongoing Review"), which may ultimately result in the Company pursuing one or more significant corporate transactions or other remedial measures. The Ongoing Review includes an evaluation of available options to regain compliance with the NYSE's continued listing standards. The Company can provide no assurances that it will be able to regain compliance with the NYSE's continued listing standards or otherwise and maintain the listing of its shares on the NYSE or the results of the Ongoing Review.

About Rite Aid

Rite Aid is a full-service pharmacy that improves health outcomes. Rite Aid is defining the modern pharmacy by meeting customer needs with a wide range of vehicles that offer convenience, including retail and delivery pharmacy, as well as services offered through our wholly owned subsidiaries, Elixir, Bartell Drugs and Health Dialog. Elixir, Rite Aid's pharmacy benefits and services company, consists of accredited mail and specialty pharmacies, prescription discount programs and an industry-leading adjudication platform to offer superior member experience and cost savings. Health Dialog provides healthcare coaching and disease management services via live online and phone health services. Regional chain Bartell Drugs has supported the health and wellness needs in the Seattle area for more than 130 years. Rite Aid employs more than 6,300 pharmacists and operates more than 2,200 retail pharmacy locations across 17 states. For more information, visit www.riteaid.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this release that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding any potential plans to cure the NYSE continued listing requirement deficiencies; the Company's expectations concerning the timing of completing the Ongoing Review; the Notice's impact on the Company's ongoing business operations or its U.S. Securities and Exchange Commission reporting requirements; and any assumptions underlying any of the foregoing. Words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," and "will" and variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties. These risks, assumptions and uncertainties are more fully described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and in other documents that we file or furnish with the Securities and Exchange Commission (the "SEC"), which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to rely on these forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any current intention, and assumes no duty, to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

Get the next $RAD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RAD

DatePrice TargetRatingAnalyst
4/7/2022$16.00 → $1.00Hold → Sell
Deutsche Bank
6/25/2021$21.00 → $12.00Neutral → Underweight
JP Morgan
More analyst ratings

$RAD
Press Releases

Fastest customizable press release news feed in the world

See more
  • Carenet Health Acquiring Health Dialog, Enhancing Clinical Team and Advancing Insights-Driven Platform Dedicated to the Business of Healthcare

    Expanded personalized population health capabilities support better health journeys for patients Carenet Health, a trusted partner in helping organizations simplify and power the business of healthcare, is excited to announce it is acquiring Health Dialog, a worldwide leader in delivering clinical decision support offerings. This acquisition enables Carenet to leverage its combined platform, analytics and clinicians to deliver greater efficiency and outcomes-based financial performance for clients. Health Dialog provides personalized population health services to health plans, providers, employers and pharmaceutical manufacturers. Carenet is acquiring all assets of Health Dialog from

    $RAD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
  • Rite Aid Receives Court Approval of "First Day" Motions to Support Business Operations

    Secures Interim Approval to Access Up to $3.45 Billion in Debtor-in-Possession Financing Continues to Serve Customers and Deliver Healthcare Products and Services Across Retail and Online Platforms Rite Aid Corporation (OTC:RADCQ) ("Rite Aid" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of New Jersey for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on October 15, 2023. The Court granted interim approval to access up to $3.45 billion in debtor-in-possession financing from certain of its lenders. This financing is expected to provide sufficient liquidity to support the Company th

    $RAD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
  • Rite Aid Corporation Appoints Jeffrey S. Stein Chief Executive Officer

    Stein Succeeds Elizabeth "Busy" Burr Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced that its Board of Directors has appointed Jeffrey S. Stein as Chief Executive Officer (CEO), Chief Restructuring Officer (CRO) and a member of the Board of Directors, effective immediately. Mr. Stein succeeds Elizabeth ("Busy") Burr, who has served as Interim CEO of Rite Aid since January 2023. Ms. Burr will continue to serve on the Company's Board. Mr. Stein brings more than three decades of experience as a leader and executive director at both public and private companies. Mr. Stein has particular expertise in supporting companies that are driving meaningful business tran

    $RAD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

$RAD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RAD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RAD
SEC Filings

See more

$RAD
Leadership Updates

Live Leadership Updates

See more
  • Rite Aid Corporation Appoints Jeffrey S. Stein Chief Executive Officer

    Stein Succeeds Elizabeth "Busy" Burr Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced that its Board of Directors has appointed Jeffrey S. Stein as Chief Executive Officer (CEO), Chief Restructuring Officer (CRO) and a member of the Board of Directors, effective immediately. Mr. Stein succeeds Elizabeth ("Busy") Burr, who has served as Interim CEO of Rite Aid since January 2023. Ms. Burr will continue to serve on the Company's Board. Mr. Stein brings more than three decades of experience as a leader and executive director at both public and private companies. Mr. Stein has particular expertise in supporting companies that are driving meaningful business tran

    $RAD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
  • Rite Aid Takes Steps to Accelerate Transformation and Position Company for Long-Term Success

    Reaches Agreement in Principle with Key Creditors on the Terms of Financial Restructuring Plan Initiates Voluntary Chapter 11 Process to Implement a Consensual Financial Restructuring That Will Significantly Reduce Debt and Enable Execution of Key Initiatives Receives Commitment for $3.45 Billion in New Financing to Support Business Operations Continuing to Serve Customers and Deliver Healthcare Products and Services Across Retail and Online Platforms Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced it has reached an agreement in principle with certain of its senior secured noteholders on the terms of a financial restructuring plan that will allow the Co

    $RAD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

$RAD
Financials

Live finance-specific insights

See more
  • Rite Aid Corporation Reports Fiscal 2024 First Quarter Results

    Revenues of $5.7 Billion, Compared to Prior Year Revenues of $6.0 Billion Retail Comparable Same Store Prescriptions Increased 4.7 Percent – Comparable Same Store Prescriptions, Excluding COVID Impact, Increased 7.4 Percent Net Loss of $306.7 Million Compared to Prior Year Net Loss of $110.2 Million – Increase Largely Attributable to a Goodwill Impairment Charge at Elixir Adjusted EBITDA of $91.7 Million, Compared to Prior Year Adjusted EBITDA of $100.1 Million Updates Fiscal 2024 Outlook Rite Aid Corporation (NYSE:RAD) today reported operating results for its first fiscal quarter ended June 3, 2023. "Our first quarter results were driven by strong script growth, solid ph

    $RAD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
  • Rite Aid to Release First Quarter Results on June 29

    Rite Aid Corporation (NYSE:RAD) will release financial results for its Fiscal 2024 First Quarter, which ended June 3, 2023, on Thursday, June 29, 2023. The company will hold an analyst call at 8:30 a.m. ET with remarks by Rite Aid's management team. The call will be broadcast at https://investors.riteaid.com. The telephone replay will be available beginning at 12:00 p.m. ET on Thursday, June 29, 2023, through 11:59 p.m. ET on July 29, 2023. To access the replay of the call, please dial (800) 770-2030 or (647) 362-9199 and enter the seven-digit reservation number 9029129. The webcast replay of the call will also be available at https://investors.riteaid.com starting at 12 p.m. ET Thursda

    $RAD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
  • Rite Aid Corporation Reports Fiscal 2023 Fourth Quarter and Full Year Results and Provides Fiscal 2024 Outlook

    Fourth Quarter Highlights: Revenues of $6.1 billion, Comparable to Prior Year Retail Comparable Same Store Prescriptions Increased 5.2 Percent – Comparable Same Store Prescriptions, Excluding COVID Impacts, Increased 9.7 Percent Net Loss per Share of $4.39, Compared to Prior Year Net Loss per Share of $7.18 Adjusted EBITDA of $128.6 million, Compared to the Prior Year Adjusted EBITDA of $106.1 million Completed Tender Offer for $165 million of our 2025 notes – Reducing Amount Outstanding to $320 million From $600 million at Beginning of Fiscal 2022 Full Year Highlights: Revenues of $24.1 billion, Compared to Prior Year Revenues of $24.6 billion Retail Comparable Same

    $RAD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

$RAD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more